Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced receiving clinical trial approvals for its VT-101 from both the National Medical Products Administration (NMPA) in China and the US Food and Drug Administration (FDA). VT-101 is a next-generation recombinant oncolytic adenovirus product that features a triple-targeted tumor regulation mechanism, three viral structural gene modifications, three serotype adenovirus chimerism, and the loading of three types of anti-cancer immune genes.
Development Focus and Market Context
The molecule is currently under development to treat advanced head and neck squamous cell carcinoma, melanoma, breast cancer, and other solid tumor types. Other similar oncolytic viral products that are commercially available include Amgen’s Imlygic (talimogene laherparepvec) and Daiichi Sankyo’s Delytact (teserpaturev/G47∆). According to the press release, Fosun has invested RMB 54.5 million in the development of its own molecule to date.- Flcube.com
